12:00 AM
 | 
Jul 16, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

PXL-01: Phase II data

Top-line data from a double-blind, European Phase II trial in 138 patients aged 15-65 undergoing flexor tendon repair surgery showed that 0.5 mL topical PXL-01 missed the primary endpoint of improving TAM2 scores at week 12 post-surgery vs. placebo. Pergamum also said that 67% of patients...

Read the full 209 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >